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Background
Limited information is available regarding HIV-1 neutral-
izing antibody (NAb) responses in clade D infection. Here
we assess the breadth and magnitude of NAb responses in
clade D or D recombinant infections, and correlate both
to clinical outcomes.
Methods
Participants were enrolled in an HIV-1 incidence cohort in
Rakai district, Uganda, between 1999 and 2004. The TZM-
bl NAb assay was performed against a panel of 10 Tier 2
pseudoviruses (2 each of clades A, B, C, D and CRF02 AG)
using one early plasma (within 1 year of seroconversion)
and one later sample (3–4 years after seroconversion)
from 21 participants (11 Clade D and 10 recombinants).
Subtype was determined using a Multi-Region Hybridiza-
tion assay.
Results
Overall, subjects showed more NAb against subtypes A,
AG and D, compared to subtypes B and C. Increased mag-
nitude was observed at later timepoints in 81% (17/21) of
subjects, with geometric mean titers against the 10 viruses
ranging from <20 to 1035. NAb breadth increased in 71%
(15/21) of subjects. No statistical differences were seen in
magnitude or breadth comparing recombinant versus
clade D infections. Strikingly, higher NAb magnitude in
both the early (P = 0.048) and late (P = 0.009) plasmas
was associated with progression to AIDS. Higher viral load
(>50,000 copies/ml) at the early timepoint was associated
with greater magnitude (p < 0.0001) and breadth (p =
0.04) of neutralization over time.
Conclusion
These data demonstrate an expansion of breadth and
magnitude of NAb over time in subtype D and D recom-
binant HIV-1 infections in Uganda, with more frequent
and potent responses directed against subtypes A, CRF02
AG, and D. Higher viral load was associated with greater
breadth and magnitude of neutralization, indicating that
increased antigen load with viral replication may be driv-
ing the expansion of pseudovirus NAb responses in this
cohort, with no observed benefit in clinical outcome.
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